Skip to main content

Research Repository

Advanced Search

All Outputs (72)

Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy? (2018)
Journal Article
Abo-zeid, Y., Urbanowicz, R. A., Thomson, B. J., Irving, W. L., Tarr, A. W., & Garnett, M. C. (2018). Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy?. International Journal of Pharmaceutics, 547(1-2), https://doi.org/10.1016/j.ijpharm.2018.06.027

Virus infections cause diseases of different severity ranged from mild infection e.g. common cold into life threatening diseases e.g. Human Immunodeficiency virus (HIV), Hepatitis B. Virus infections represent 44% of newly emerging infections. Althou... Read More about Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy?.

Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: a possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles (2018)
Journal Article
Abo-zeid, Y., Mantovani, G., Irving, W. L., & Garnett, M. (2018). Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: a possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles. Journal of Drug Delivery Science and Technology, 46, https://doi.org/10.1016/j.jddst.2018.05.027

Nucleoside analogues are active therapeutic agents for different types of diseases e.g. Cancer and virus infections. However, they are associated with several side effects due to off-target accumulation. Particulate delivery systems such as nanoparti... Read More about Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: a possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles.

Pretreatment lesions on magnetic resonance imaging in patients with hepatitis C virus infection diagnosed with hepatocellular carcinoma after initiating direct-acting antiviral therapy (2018)
Journal Article
Scott, R. A., Aithal, G. P., Francis, S. T., & Irving, W. L. (2018). Pretreatment lesions on magnetic resonance imaging in patients with hepatitis C virus infection diagnosed with hepatocellular carcinoma after initiating direct-acting antiviral therapy. Gastroenterology, 154(6), https://doi.org/10.1053/j.gastro.2017.12.047

Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus (2018)
Journal Article
Llibre, A., Shimakawa, Y., Mottez, E., Ainsworth, S., Buivan, T., Firth, R., …Duffy, D. (2018). Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut, 67(11), 2017-2024. https://doi.org/10.1136/gutjnl-2017-315783

Objective: Recently approved direct acting antivirals provide transformative therapies for chronic hepatitis C virus (HCV) infection. The major clinical challenge remains to identify the undiagnosed patients worldwide, many of whom live in low-income... Read More about Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.

Understanding hepatitis C intervention success: qualitative findings from the HepCATT study (2018)
Journal Article
Harris, M., Bonnington, O., Harrison, G., Hickman, M., & Irving, W. L. (in press). Understanding hepatitis C intervention success: qualitative findings from the HepCATT study. Journal of Viral Hepatitis, https://doi.org/10.1111/jvh.12869

The United Kingdom has committed to eliminating viral hepatitis as a public health threat. Innovative interventions for marginalized populations are required to realize this goal. In 2016, the HepCATT study team implemented a complex hepatitis C (HCV... Read More about Understanding hepatitis C intervention success: qualitative findings from the HepCATT study.

Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease (2018)
Journal Article
Kendall, T., Dolman, G., Duff, C., Paish, E. C., Zaitoun, A., Irving, W. L., …Guha, I. N. (2018). Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease. Histopathology, 73(1), 90-100. https://doi.org/10.1111/his.13499

Aims. Needle biopsy remains essential for diagnosis in assessment of liver disease, although there remains associated risk. Examination is largely limited to subjective evaluation and biopsies are not exploited to provide personalised prognostic info... Read More about Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease.

Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review (2018)
Journal Article
Walker, A. J., Peacock, C. J., Pedergnana, V., & Irving, W. L. (in press). Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review. Journal of Viral Hepatitis, 25(5), https://doi.org/10.1111/jvh.12871

Hepatitis C virus (HCV)-infected patients are at risk of developing hepatocellular carcinoma (HCC). Individuals at heightened riskcould be targeted by intensive follow-up surveillance. We have conducted a systematic review of the literature to identi... Read More about Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review.

Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals (2017)
Journal Article
Simmons, R., Ireland, G., Irving, W., Hickman, M., Sabin, C., Ijaz, S., …Mandal, S. (in press). Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals. Journal of Viral Hepatitis, https://doi.org/10.1111/jvh.12844

Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C (HCV) in England. Establishing a cascade of care informs targeted interventions for improving case-finding, referral, treatment uptake and retention i... Read More about Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.

SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis (2017)
Journal Article
Athwal, V. S., Pritchett, J., Llewellyn, J., Martin, K., Camacho, E., Raza, S. M., …Hanley, K. P. (in press). SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis. EMBO Molecular Medicine, 9(12), https://doi.org/10.15252/emmm.201707860

Fibrosis and organ failure is a common endpoint for many chronic liver diseases. Much is known about the upstream inflammatory mechanisms provoking fibrosis and downstream potential for tissue remodeling. However, less is known about the transcriptio... Read More about SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis.

Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis (2017)
Journal Article
Manouchehrinia, A., Tanasescu, R., Kareem, H., Jerca, O. P., Jabeen, F., Shafei, R., …Constantinescu, C. S. (in press). Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. Journal of NeuroVirology, https://doi.org/10.1007/s13365-017-0569-1

Varicella zoster virus (VZV) infection has been implicated in multiple sclerosis (MS), but direct causal involvement has been disputed. Nevertheless, knowledge of VZV exposure is important, given the risk of serious complications of first exposure wh... Read More about Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis.

Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK (2017)
Journal Article
Hudson, B., Walker, A. J., & Irving, W. L. (2017). Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK. Journal of Medical Virology, 89(12), 2158-2164. https://doi.org/10.1002/jmv.24848

© 2017 The Authors. Journal of Medical Virology Published by Wiley Periodicals, Inc. Designing services with the capacity and expertise to meet the needs of the chronic hepatitis C (CHC) population in the era of direct acting antivirals (DAAs), and w... Read More about Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016)
Journal Article
International Liver Disease Genetics Consortium, Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., …Eslam, M. (2016). MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 7(1), Article 12757. https://doi.org/10.1038/ncomms12757

© 2016 The Author(s). Cirrhosis likely shares common pathophysiological pathways despite arising from a variety of liver diseases. A recent GWAS identified rs641738, a polymorphism in the MBOAT7 locus, as being associated with the development of alco... Read More about MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis (2016)
Journal Article
Cheung, M. C., Walker, A. J., Hudson, B. E., Verma, S., McLauchlan, J., Mutimer, D. J., …Irving, W. L. (2016). Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 65(4), 741-747. https://doi.org/10.1016/j.jhep.2016.06.019

Direct-acting antivirals have become widely used for patients with chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are excellent and early improvements in liver function, at least in a proportion of patients, h... Read More about Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis (2016)
Journal Article
Foster, G. R., Irving, W. L., Cheung, M. C., Walker, A. J., Hudson, B. E., Verma, S., …Agarwal, K. (2016). Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 64(6), 1224-1231. https://doi.org/10.1016/j.jhep.2016.01.029

© 2016 European Association for the Study of the Liver. Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared outcom... Read More about Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

Clinical care pathways for patients with hepatitis C: reducing critical barriers to effective treatment. (2016)
Journal Article
Howes, N., Lattimore, S., Irving, W. L., & Thomson, B. J. (2016). Clinical care pathways for patients with hepatitis C: reducing critical barriers to effective treatment. 00 Journal not listed, 3(1), doi:10.1093/ofid/ofv218

Background: Engagement of individuals infected with hepatitis C virus (HCV) with care pathways remains a major barrier to realizing the benefits of new and more effective antiviral therapies. After an exploratory study, we have undertaken an evidence... Read More about Clinical care pathways for patients with hepatitis C: reducing critical barriers to effective treatment..

A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance (2015)
Journal Article
Urbanowicz, R. A., McClure, P., Brown, R. J., Tsoleridis, T., Persson, M. A., Krey, T., …Tarr, A. W. (2016). A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance. Journal of Virology, 90(7), 3288-3301. https://doi.org/10.1128/JVI.02700-15

Despite significant advances in the treatment of hepatitis C virus (HCV) infection, the need to develop preventative vaccines remains. Identification of the best vaccine candidates and evaluation of their performance in preclinical and clinical devel... Read More about A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance.

Serum autoantibody measurement for the detection of hepatocellular carcinoma (2014)
Journal Article
Middleton, C. H., Irving, W., Robertson, J. F., Murray, A., Parsy-Kowalska, C. B., Macdonald, I. K., …Thomson, B. J. (2014). Serum autoantibody measurement for the detection of hepatocellular carcinoma. PLoS ONE, 9(8), 1-9. https://doi.org/10.1371/journal.pone.0103867

Background: Individuals with liver disease, and especially those with Hepatitis B or C, are at an increased risk of developing hepatocellular carcinoma (HCC) which is the third most common cause of cancer-related death worldwide. Inadequate screening... Read More about Serum autoantibody measurement for the detection of hepatocellular carcinoma.

Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry (2014)
Journal Article
Hamed, M. R., Brown, R. J., Zothner, C., Urbanowicz, R. A., Mason, C. P., Krarup, A., …Tarr, A. W. (2014). Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry. Journal of Innate Immunity, 6(5), 676-684. https://doi.org/10.1159/000362209

L-ficolin is a soluble pattern recognition molecule expressed by the liver that contributes to innate immune defense against microorganisms. It is well described that binding of L-ficolin to specific pathogen-associated molecular patterns activates t... Read More about Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry.